Real Estate - Real Estate - Services - NASDAQ - US
$ 3.15
4.3 %
$ 3.45 M
Market Cap
-0.16
P/E
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform.[ Read More ]
The intrinsic value of one ALBT stock under the base case scenario is HIDDEN Compared to the current market price of 3.15 USD, Avalon GloboCare Corp. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ALBT
FINANCIALS
1.26 M
REVENUE
-15.8 M
OPERATING INCOME
-16.7 M
NET INCOME
-6.5 M
OPERATING CASH FLOW
-22.2 K
INVESTING CASH FLOW
4.83 M
FINANCING CASH FLOW
328 K
REVENUE
-1.5 M
OPERATING INCOME
-2.13 M
NET INCOME
-1.08 M
OPERATING CASH FLOW
-100 K
INVESTING CASH FLOW
1.07 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Avalon GloboCare Corp.
| Current Assets | 285 K |
| Cash & Short-Term Investments | 285 K |
| Receivables | 235 K |
| Other Current Assets | -235 K |
| Non-Current Assets | 20.3 M |
| Long-Term Investments | 19.3 M |
| PP&E | 166 K |
| Other Non-Current Assets | 844 K |
| Current Liabilities | 6.76 M |
| Accounts Payable | 0 |
| Short-Term Debt | 2.18 M |
| Other Current Liabilities | 4.58 M |
| Non-Current Liabilities | 6.45 M |
| Long-Term Debt | 6.45 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Avalon GloboCare Corp.
| Revenue | 1.26 M |
| Cost Of Revenue | 1.02 M |
| Gross Profit | 238 K |
| Operating Expenses | 16 M |
| Operating Income | -15.8 M |
| Other Expenses | 953 K |
| Net Income | -16.7 M |
RATIOS
18.97%
GROSS MARGIN
-1254.59%
OPERATING MARGIN
-1330.51%
NET MARGIN
-226.73%
ROE
-81.17%
ROA
-99.27%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Avalon GloboCare Corp.
| Net Income | -16.7 M |
| Depreciation & Amortization | 330 K |
| Capital Expenditures | -22.2 K |
| Stock-Based Compensation | 1.18 M |
| Change in Working Capital | -35.1 K |
| Others | 8.69 M |
| Free Cash Flow | -6.53 M |
Wall Street Analysts Price Targets
Avalon GloboCare Corp.
ALBT has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Avalon GloboCare Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
4 years ago
Apr 01, 2020
|
Bought 1 M USD
|
Lu Wenzhao
director, 10 percent owner: |
+ 645161
|
1.55 USD |
|
4 years ago
Apr 01, 2020
|
Bought 1 M USD
|
Lu Wenzhao
director, 10 percent owner: |
+ 645161
|
1.55 USD |
|
5 years ago
Jun 07, 2019
|
Bought 27.6 K USD
|
Lu Wenzhao
director, 10 percent owner: |
+ 15000
|
1.84 USD |
|
5 years ago
Apr 18, 2019
|
Bought 27.6 K USD
|
Lu Wenzhao
Director |
+ 15000
|
1.84 USD |
|
5 years ago
Jun 06, 2019
|
Bought 42.6 K USD
|
Lu Wenzhao
director, 10 percent owner: |
+ 21000
|
2.03 USD |
|
5 years ago
Apr 18, 2019
|
Bought 42.6 K USD
|
Lu Wenzhao
Director |
+ 21000
|
2.03 USD |
|
5 years ago
Apr 18, 2019
|
Bought 2 M USD
|
Lu Wenzhao
director, 10 percent owner: |
+ 2000000
|
1 USD |
|
5 years ago
Apr 18, 2019
|
Bought 2 M USD
|
Lu Wenzhao
director, 10 percent owner: |
+ 2000000
|
1 USD |
|
6 years ago
Dec 15, 2017
|
Bought 260 USD
|
Sukel Steven Philip
Director |
+ 100
|
2.6 USD |
|
6 years ago
Dec 15, 2017
|
Bought 600 USD
|
Sukel Steven Philip
Director |
+ 300
|
2 USD |
|
6 years ago
Dec 15, 2017
|
Bought 1.6 K USD
|
Sukel Steven Philip
Director |
+ 600
|
2.67 USD |
|
6 years ago
Nov 20, 2017
|
Bought 900 USD
|
Sukel Steven Philip
Director |
+ 500
|
1.8 USD |
|
6 years ago
Nov 20, 2017
|
Bought 1.62 K USD
|
Sukel Steven Philip
Director |
+ 900
|
1.8 USD |
|
6 years ago
Nov 20, 2017
|
Bought 995 USD
|
Sukel Steven Philip
Director |
+ 500
|
1.99 USD |
|
6 years ago
Nov 20, 2017
|
Bought 567 USD
|
Sukel Steven Philip
Director |
+ 300
|
1.89 USD |
|
6 years ago
Nov 20, 2017
|
Bought 190 USD
|
Sukel Steven Philip
Director |
+ 100
|
1.9 USD |
|
6 years ago
Nov 20, 2017
|
Bought 594 USD
|
Sukel Steven Philip
Director |
+ 300
|
1.98 USD |
|
6 years ago
Nov 20, 2017
|
Bought 2.92 K USD
|
Sukel Steven Philip
Director |
+ 1500
|
1.95 USD |
|
6 years ago
Nov 20, 2017
|
Bought 199 USD
|
Sukel Steven Philip
Director |
+ 100
|
1.99 USD |
|
6 years ago
Nov 20, 2017
|
Bought 1.95 K USD
|
Sukel Steven Philip
Director |
+ 1000
|
1.95 USD |
|
6 years ago
Nov 20, 2017
|
Bought 198 USD
|
Sukel Steven Philip
Director |
+ 100
|
1.98 USD |
|
7 years ago
Apr 01, 2017
|
Bought 199 USD
|
Sukel Steven Philip
Director |
+ 100
|
1.99 USD |
|
7 years ago
Apr 01, 2017
|
Bought 199 USD
|
Sukel Steven Philip
Director |
+ 100
|
1.99 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2.75 K USD
|
Sukel Steven Philip
Director |
+ 1100
|
2.5 USD |
|
7 years ago
Apr 01, 2017
|
Bought 625 USD
|
Sukel Steven Philip
Director |
+ 250
|
2.5 USD |
|
7 years ago
Apr 01, 2017
|
Bought 700 USD
|
Sukel Steven Philip
Director |
+ 200
|
3.5 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2.49 K USD
|
Sukel Steven Philip
Director |
+ 815
|
3.05 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2.1 K USD
|
Sukel Steven Philip
Director |
+ 700
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2.4 K USD
|
Sukel Steven Philip
Director |
+ 750
|
3.2 USD |
|
7 years ago
Apr 01, 2017
|
Bought 650 USD
|
Sukel Steven Philip
Director |
+ 200
|
3.25 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2.44 K USD
|
Sukel Steven Philip
Director |
+ 750
|
3.25 USD |
|
7 years ago
Apr 01, 2017
|
Bought 320 USD
|
Sukel Steven Philip
Director |
+ 100
|
3.2 USD |
|
7 years ago
Apr 01, 2017
|
Bought 325 USD
|
Sukel Steven Philip
Director |
+ 100
|
3.25 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2 K USD
|
Sukel Steven Philip
Director |
+ 500
|
4 USD |
|
7 years ago
Apr 01, 2017
|
Bought 1.9 K USD
|
Sukel Steven Philip
Director |
+ 500
|
3.8 USD |
|
7 years ago
Apr 01, 2017
|
Bought 1.8 K USD
|
Sukel Steven Philip
Director |
+ 500
|
3.6 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2.01 K USD
|
Sukel Steven Philip
Director |
+ 600
|
3.35 USD |
|
7 years ago
Apr 01, 2017
|
Bought 359 USD
|
Sukel Steven Philip
Director |
+ 100
|
3.59 USD |
|
7 years ago
Apr 01, 2017
|
Bought 708 USD
|
Sukel Steven Philip
Director |
+ 200
|
3.54 USD |
|
7 years ago
Apr 01, 2017
|
Bought 339 USD
|
Sukel Steven Philip
Director |
+ 100
|
3.39 USD |
|
7 years ago
Apr 01, 2017
|
Bought 334 USD
|
Sukel Steven Philip
Director |
+ 100
|
3.34 USD |
|
7 years ago
Apr 01, 2017
|
Bought 1.58 K USD
|
Sukel Steven Philip
Director |
+ 500
|
3.15 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2.4 K USD
|
Sukel Steven Philip
Director |
+ 800
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought 334 USD
|
Sukel Steven Philip
Director |
+ 100
|
3.34 USD |
|
7 years ago
Apr 01, 2017
|
Bought 2.25 K USD
|
Sukel Steven Philip
Director |
+ 750
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought 3 K USD
|
Sukel Steven Philip
Director |
+ 1000
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought 295 USD
|
Sukel Steven Philip
Director |
+ 100
|
2.95 USD |
|
7 years ago
Apr 01, 2017
|
Bought 600 USD
|
Sukel Steven Philip
Director |
+ 200
|
3 USD |
|
7 years ago
Apr 01, 2017
|
Bought 195 USD
|
Sukel Steven Philip
Director |
+ 100
|
1.95 USD |
|
7 years ago
Apr 01, 2017
|
Bought 200 USD
|
Sukel Steven Philip
Director |
+ 100
|
2 USD |
|
7 years ago
Apr 01, 2017
|
Bought 300 K USD
|
Sukel Steven Philip
Director |
+ 200000
|
1.5 USD |
|
7 years ago
Apr 20, 2017
|
Sell 2.5 M USD
|
Lu Wenzhao
director, 10 percent owner: |
- 5000000
|
0.5 USD |
|
7 years ago
Apr 20, 2017
|
Sell 2.5 M USD
|
Lu Wenzhao
Director |
- 5000000
|
0.5 USD |
7. News
Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. The MOU provides Avalon with an exclusivity period of 120 days (the “Exclusivity Period”), during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive agreement regarding the proposed strategic collaboration.
globenewswire.com
- 3 weeks ago
Why Is Avalon GloboCare (ALBT) Stock Up 173% Today?
Avalon GloboCare (NASDAQ: ALBT ) stock is up on Wednesday alongside news of a new medical device being launched by Laboratory Services MSO. Laboratory Services MSO is preparing to launch its GeeWhiz External Condom Catheter in the third quarter of 2024.
investorplace.com
- 3 months ago
Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection
globenewswire.com
- 3 months ago
Avalon GloboCare unveils KetoAir breathalyzer at KetoCon 2024
Avalon GloboCare Corp (NASDAQ:ALBT) said it had successfully launched its KetoAir breathalyzer in the US at the Hack Your Health by KetoCon 2024 Conference. Avalon CEO David Jin told shareholders that the booth at the event in Austin “attracted a diverse group of potential clients and partners, including doctors, disease management companies, health and keto coaches, consumers, keto product manufacturers, and service providers interested in establishing a marketplace on our app and device.
proactiveinvestors.com
- 4 months ago
Why Is Avalon Globocare (ALBT) Stock Down 27% Today?
Avalon Globocare (NASDAQ: ALBT ) stock is down on Tuesday but only after the commercial real estate company's shares underwent a massive rally on Monday on a recent filing. That rally came after the company filed its Form 10-Q with the Securities and Exchange Commission (SEC).
investorplace.com
- 5 months ago
Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report
FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”).
globenewswire.com
- 5 months ago
Avalon GloboCare launches KetoAir breathalyzer in the US
Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.
proactiveinvestors.com
- 6 months ago
Avalon GloboCare launches KetoAir breathalyzer in the US
Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.
proactiveinvestors.com
- 6 months ago
Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference
FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.
globenewswire.com
- 6 months ago
Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer
Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regions, including North America, South America, the United Kingdom and the European Union. Shares of the biotechnology company added 19% at US$0.36 before Thursday's opening bell on the news.
proactiveinvestors.com
- 7 months ago
Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union
FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union.
globenewswire.com
- 7 months ago
Avalon GloboCare engages ChtrBx to develop marketing launch plan for KetoAir
Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir in North America, South America, the United Kingdom (UK) and the European Union (EU). The developer of innovative cell-based technology, cellular therapy and precision diagnostics said KetoAir functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management.
proactiveinvestors.com
- 10 months ago
8. Profile Summary
Avalon GloboCare Corp. ALBT
COUNTRY
US
INDUSTRY
Real Estate - Services
MARKET CAP
$ 3.45 M
Dividend Yield
0.00%
Description
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Contact
4400 Route 9 South, Freehold, NJ, 07728
https://www.avalon-globocare.com
IPO Date
March 27, 2018
Employees
4
Officers
Dr. David K. Jin M.D., Ph.D.
Chief Executive Officer, President & Director
Ms. Meng Li
Chief Operating Officer & Secretary
Ms. Luisa Ingargiola
Chief Financial Officer